AGS-v: Ph I started

hVIVO said NIH’s National Institute of Allergy and Infectious Disease (NIAID) began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate 2 injections of AGS-v with or without adjuvant given 21 days apart in about 60 healthy adults. After vaccination, subjects will undergo a controlled exposure to uninfected, biting mosquitoes...